Parker H. “Pete” Petit, chairman and CEO, stated, “Dr. Matthews brings over 20 years of experience encompassing programs from discovery into Phase 3 clinical development for devices, orthobiologics, combination products, and new chemical entities for osteoarthritis, cartilage repair, and regenerative medicine. She is an accomplished scientific leader with broad-ranging expertise in orthopedic and rheumatologic diseases, among other therapeutic areas, and she has significant functional experience in cellular and gene therapy, biomaterials and growth factors.”
Matthews most recently served as chief medical officer at Histogenics Corporation, where she supervised all clinical and medical affairs activities with strategic oversight of various U.S. and global development programs across biologics, drugs and device platforms.
Prior to Histogenics, Matthews spent 12 years at Genzyme Corporation and Sanofi Genzyme. During her tenure at Genzyme, Matthews held progressively more responsible leadership positions and was involved in clinical and preclinical development and/or post-market support of cell, gene, growth factor, small molecule and biomaterialbased products in the orthopedic and rheumatologic space. Matthews last served with Sanofi Genzyme in the role of senior director and global head of Bone and Joint Disease Research and Development.
Matthews earned her DVM and Ph.D. from Cornell University. Her concentration was in cell and molecular biology of osteoarthritis.
“The addition of Dr. Matthews to our staff is an important step in our continued expansion into biopharmaceuticals," said Bill Taylor, MiMedx president and chief operating officer. "We will continue to expand our clinical and scientific talent and resources to further drive our growth in this area. We are very excited to welcome Dr. Matthews to our organization.”
The company also reaffirmed its previously communicated revenue expectations for the third quarter of 2017. “In our press releases of September 5 and September 13, 2017, we communicated that we expected to exceed the $80 million upper end of our forecasted third quarter revenue range in spite of the disruption from Hurricane Harvey and Hurricane Irma. Our preliminary revenue estimates clearly show that our forecasting was correct. We are experiencing robust revenue growth, and we look forward to reporting our actual third quarter revenue,” added Petit.
MiMedx is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. Its our mission to give physicians products and tissues to help the body heal itself. MiMedx processes the human placental tissue utilizing its proprietary PURION Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1 million allografts to date for application in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare.